Plus Therapeutics Inc

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. Show More...

  • Website https://www.plustherapeutics.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 0.29 USD
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -4284.55 -4355.96 -3927.51 -2784.96 -3427.64 -1035.0 -640.0 -411.5 -86.98 -8.27 0.37
    Dividends USD
    Payout Ratio % *
    Shares Mil 1.0 2.0
    Book Value Per Share * USD 3144.05 1504.85 699.35 -319.28 -236.7 183.05 314.87 67.61 20.69 0.04 0.02
    Free Cash Flow Per Share * USD -3758.78 -4534.21 -4064.38 -3721.77 -3407.97 -1245.3 -655.5 -356.34 -110.88 -19.86
    Return on Assets % -60.36 -55.06 -68.11 -61.37 -95.41 -50.79 -60.98 -80.52 -54.39 -48.46 -41.15
    Financial Leverage (Average) 2.9 5.18 6.7 13.43 3.09 3.15 2.43 4.59 20.02 246.67
    Return on Equity % -286.17 -197.76 -393.62 -546.09 -596.71 -190.12 -222.32 -165.94 -358.37 -475.8
    Return on Invested Capital % -117.82 -79.63 -90.96 -77.81 -77.79 -60.72 -111.43 -57.51 -58.07 -47.87
    Interest Coverage -12.34 -12.13 -8.53 -6.71 -7.55 -4.55 -7.51 -10.07 -5.57 -0.77 -0.13
    Current Ratio 4.46 5.54 1.93 1.65 1.36 2.52 1.5 0.81 0.55 1.37 1.18
    Quick Ratio 4.14 5.01 1.69 1.33 1.0 1.85 1.11 0.53 0.32 1.3 1.14
    Debt/Equity 0.58 2.21 2.0 7.38 1.37 1.0 0.56 7.34